Conversations in Drug Development
Navigating the FDA Landscape: More Changes, and What's Next?
· 27 min · Episodio 24
Note dell’episodio
In this episode, Eric Hardter and guest Kelsey Lenoch discuss recent US FDA developments, including leadership changes at CBER and CDER, staffing impacts on orphan product reviews, and the new Rare Disease Evidence Principles aimed at accelerating approvals for rare and ultra-rare conditions.
They also explore evolving trial endpoints in oncology (including surrogate measures and ctDNA), transparency moves such as the public release of Complete Response Letters and the industry’s reactions, updates on the National Priority Voucher Program, and the FDA Pre-Check initiative to boost domestic…
Sito web: conversationsindrugdevelopmentwithboyds.podbean.com
